Oncology Brothers: Practice-Changing Cancer Discussions

By Oncology Brothers

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology &

... more

4.9

4242 ratings

FAQs about Oncology Brothers: Practice-Changing Cancer Discussions:

How many episodes does Oncology Brothers: Practice-Changing Cancer Discussions have?

The podcast currently has 287 episodes available.

Best of Oncology Brothers: Practice-Changing Cancer Discussions

The most played episodes among Podcast App listeners.

Number 1: Camizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6
Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial. We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life. Key topics covered in this episode: Overview of the SERENA-6 trial and its findings The role of ESR1 mutations in treatment resistance The efficacy and safety profile of camizestrant Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice Management of side effects, including bradycardia and QT prolongation Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers
September 16, 202621min
Number 2: Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann
Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute. Join us as we explored: The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs The importance of spleen reduction and its correlation with patient outcomes and survival Insights into the side effect profiles of various treatments and the future of myelofibrosis management Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers
September 07, 202625min
Number 3: SURPASS-ET: FDA Approval of Ropeginterferon alfa-2b in Essential Thrombocythemia (ET)
Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV). The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea. Key topics covered in this episode included: Overview of the SURPASS-ET study and its significance Efficacy and tolerability of ropeginterferon alfa-2b in ET Side effect profiles of ropeginterferon alfa-2b vs anagrelide The importance of monitoring JAK2 allele burden and its clinical relevance Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics! #EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers
September 14, 202623min
Number 4: Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET). We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: ⁠https://x.com/oncbrothers⁠ ⁠Instagram: ⁠https://www.instagram.com/oncbrothers⁠ Website: ⁠https://oncbrothers.com/⁠ Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers
September 04, 202627min
Number 5: VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall
Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications. Key topics discussed included: The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies Insights into dosing, side effects, and the drug's impact on patient quality of life Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes! #Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology
September 02, 202620min